Comparing our new results with the ones in 1998, misdiagnosis rate was less and time to put a correct diagnosis was shorter. However, proper diagnosis at first sight is still a problem among neurologists even the typical EEG changes are present.

Background and Objectives:Declines in stroke admission, intravenous thrombolysis, and mechanical thrombectomy volumes were reported during the first wave of the COVID-19 pandemic. There is a paucity of data on the longer-term effect of the pandemic on stroke volumes over the course of a year and through the second wave of the pandemic. We sought to measure the impact of the COVID-19 pandemic on the volumes of stroke admissions, intracranial hemorrhage (ICH), intravenous thrombolysis (IVT), and mechanical thrombectomy over a one-year period at the onset of the pandemic (March 1, 2020, to February 28, 2021) compared with the immediately preceding year (March 1, 2019, to February 29, 2020).Methods:We conducted a longitudinal retrospective study across 6 continents, 56 countries, and 275 stroke centers. We collected volume data for COVID-19 admissions and 4 stroke metrics: ischemic stroke admissions, ICH admissions, intravenous thrombolysis treatments, and mechanical thrombectomy procedures. Diagnoses were identified by their ICD-10 codes or classifications in stroke databases.Results:There were 148,895 stroke admissions in the one-year immediately before compared to 138,453 admissions during the one-year pandemic, representing a 7% decline (95% confidence interval [95% CI 7.1, 6.9]; p<0.0001). ICH volumes declined from 29,585 to 28,156 (4.8%, [5.1, 4.6]; p<0.0001) and IVT volume from 24,584 to 23,077 (6.1%, [6.4, 5.8]; p<0.0001). Larger declines were observed at high volume compared to low volume centers (all p<0.0001). There was no significant change in mechanical thrombectomy volumes (0.7%, [0.6,0.9]; p=0.49). Stroke was diagnosed in 1.3% [1.31,1.38] of 406,792 COVID-19 hospitalizations. SARS-CoV-2 infection was present in 2.9% ([2.82,2.97], 5,656/195,539) of all stroke hospitalizations.Discussion:There was a global decline and shift to lower volume centers of stroke admission volumes, ICH volumes, and IVT volumes during the 1st year of the COVID-19 pandemic compared to the prior year. Mechanical thrombectomy volumes were preserved. These results suggest preservation in the stroke care of higher severity of disease through the first pandemic year.Trial Registration Information:This study is registered underNCT04934020.

No abstract

Background: The humanitarian response for Syria has been largely managed either from within Syria or from neighboring countries, particularly Turkey. This study was aimed at determining the sociodemographic and clinical profiles of Syrian asylum-seekers admitted to our clinic, changes in patient number across years, and the percentage of patients on follow-ups. Methods: Syrian patients who were admitted to the neurology outpatient clinics, neurology emergency department (ED), and hospitalized in the neurology clinics were included in the study. Age, gender, number of admissions, year of admissions, chief complaints, diagnoses, and follow-up percentages of patients were recorded. Results: The total number of Syrian patients who were first admitted to our hospital and consulted from other clinics, were found to be 763 (ED: 609 [79.8%], outpatient: 134 [17.6%] consultation: 20 [2.6%]). A total of 543 (96.1%) of the patients with a neurological disorder did not come to the follow-ups even though their conditions required regular follow-ups. The most common complaints were headache (24.2%), fainting (16.1%), weakness (11.9%), and dizziness (10%). Conclusion: Most of the patients admitted to our hospital did not come to the follow-ups and information regarding their treatments could not be obtained. Even though the Republic of Turkey provided the Syrian asylum-seekers with free medical care, utilization of these resources may be limited because of socioeconomic issues.

Objectives: Zonisamide (ZNS) is a newer generation antiepileptic drug used against partial and generalized seizures. The aim of this study was to investigate the safety and efficacy of ZNS in refractory epilepsy patients under clinical follow-up in our center.Methods: A total of 45 patients were found eligible. Six patients observed for less than six months were excluded. Age, gender, seizure types, neurological examination, magnetic resonance imaging, EEG features, number of concomitant antiepileptic drugs, seizure reduction, and adverse effects were noted. Results:The remaining 39 patients, with a mean age of 34.3±9.3 years, were evaluated. The seizure types were complex partial seizure (CPS) and generalized tonic-clonic seizure (GTCS) in 74.4%, GTCS in 10.3%, CPS in 7.7%, GTCS and myoclonia in 5.2%, and GTCS, absence and myoclonia in 2.6% patients. Nineteen of the 39 patients stopped treatment due to aggrevated seizures, unchanged seizure frequency, or side effects. A seizure frequency reduction of 25% was noted in 1, 50% in 5, and 75% in 7 patients. Three patients became seizure-free. Shortening of the seizure period was noted in four patients. Good clinical response was achieved in between 7-80 months' long treatment with 100-400 mg/day doses. Conclusion:ZNS is used as a safe, tolerable, and effective add-on alternative therapy for refractory epilepsy patients in our center.